Sarbani Chaudhuri
Known title: See RemarksCIK: 0002064940
Associated companies
Transaction History
| RCKT | ▼ Sell | Open Market | 4,701 | $16K | 8/11/2026 | View on chart |
| RCKT | ▼ Sell | Open Market | 17,650 | $68K | 5/7/2026 | View on chart |
| RCKT | ▲ Buy | Grant | 125,924 | $0 | 2/11/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Rocket Pharmaceuticals Gets FDA Alignment on Heart Drug Trial
Rocket Pharmaceuticals has secured FDA alignment on a trial for its heart drug, which may help address prior safety concerns. This regulatory step is significant for the company's development timeline. The stock is currently trading near its 52-week low, reflecting ongoing market caution despite this progress.
Rocket Pharmaceuticals Gets FDA Alignment on Heart Drug Trial. Rocket Pharmaceuticals has secured FDA alignment on a trial for its heart drug, which may help address prior safety concerns. This regulatory step is significant for the company's development timeline. The stock is currently trading near its 52-week low, reflecting ongoing market caution despite this progress.